Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
Dr. Bristow Dr. Michael Bristow, President and CEO, ARCA biopharma, Inc. * rNAPc2 development focused on unmet need for treatments in hospitalized COVID-19 patients, including after availability of vaccines * rNAPc2 is the only novel compound being developed for COVID-19 Associated Coagulopathy * Topline trial data anticipated in the second quarter of 2021 * Data from this development program will also inform potential development in additional RNA virus-associated diseasesWESTMINSTER, Colo....
WESTMINSTER, Colo., Dec. 09, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), today announced that its 2020 Annual Meeting of Stockholders, scheduled for Thursday, December 10, 2020 at 9:00 a.m. MT, now will be held at the company’s offices located at 10170 Church Ranch Way, Suite 100, Westminster, CO 80021, approximately one-quarter mile from the previously noticed location. The meeting location change is due to the COVID-19 related unavailability of the previously noticed meeting ...
Shares of ARCA Biopharma Inc. gained 5.5% in trading on Monday after the company said it received a Fast-Track designation from the Food and Drug Administration for its mid-stage experimental COVID-19 treatment. ARCA plans to launch a Phase 2b clinical trial enrolling 100 hospitalized COVID-19 patients next month, and it anticipates that the first round of topline data from the study will be available in the second quarter of next year. ARCA's stock is down 31.9% so far this year, while the S&P...
Dr. Bristow Dr. Michael Bristow, President and CEO, ARCA biopharma, Inc. * Development addresses need for treatments for patients hospitalized with COVID-19 whether vaccines are available or not * AB201 is the only novel compound being developed for COVID Associated Coagulopathy * Initiation of ASPEN-COVID-19 Phase 2b clinical trial anticipated in December * Topline trial data anticipated Q2 2021WESTMINSTER, Colo., Nov. 23, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a bi...
Dr. Bristow Dr. Michael Bristow, President and CEO, ARCA biopharma, Inc. * Initiation of Phase 2b clinical trial evaluating AB201 as a potential treatment for COVID19 anticipated in fourth quarter * Topline data from trial anticipated Q2 2021WESTMINSTER, Colo., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported finan...
Dr. Bristow Dr. Michael Bristow, President and CEO, ARCA biopharma, Inc. * Initiation of Phase 2b clinical trial anticipated in Q4 2020 * Trial to enroll approximately 100 patients hospitalized with COVID-19 * Topline data anticipated Q2 2021 WESTMINSTER, Colo., Oct. 07, 2020 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced the U...